Literature DB >> 12592327

Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome.

J-H Lee1, J-H Lee1, Y-R Shin, J-S Lee, W-K Kim, H-S Chi, C-J Park, E-J Seo, K-H Lee.   

Abstract

We retrospectively studied 227 patients with MDS (1) to identify the prognostic factors of survival and acute leukemia evolution in Korean patients with MDS, (2) to apply different prognostic scoring systems to the same group of patients, and (3) to compare the FAB with the WHO classification. Six scoring systems were applied to the patients, and the FAB and WHO classifications were compared. The patients' median age was 57 years. The median survival time was 21 months, and age, dysgranulopoiesis and the IPSS cytogenetic groups were independent prognostic factors for survival. Acute leukemia occurred in 34 patients, and the cumulative incidence was 27.1% at 3 years. Marrow blast percentage was the only independent prognostic factor for acute leukemia evolution. Most scoring systems successfully discriminated risk groups for survival and acute leukemia evolution, but patient distribution into risk groups varied according to the scoring systems. Refractory cytopenia with multilineage dysplasia and RAEB II seemed to have different prognoses from RA or RARS and RAEB I, respectively. In summary, our MDS patients had different disease natures from those of Western countries regarding clinical features, prognostic factors and cytogenetic profiles. Although the WHO classification seems to improve the FAB classification, further studies are warranted to validate the utility of the WHO classification before it is accepted for routine clinical use. Our study has the limitations of retrospective analysis, and our results should be verified in future prospective studies.

Entities:  

Mesh:

Year:  2003        PMID: 12592327     DOI: 10.1038/sj.leu.2402798

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  23 in total

1.  Prognosis in myelodysplastic syndromes: are the new classifications useful?

Authors:  Naomi Galili; Azra Raza
Journal:  Curr Hematol Malig Rep       Date:  2008-01       Impact factor: 3.952

Review 2.  Murine xenogeneic models of myelodysplastic syndrome: an essential role for stroma cells.

Authors:  Xiang Li; H Joachim Deeg
Journal:  Exp Hematol       Date:  2013-10-11       Impact factor: 3.084

3.  A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome.

Authors:  Je-Hwan Lee; Jun Ho Jang; Jinny Park; Seonyang Park; Young-Don Joo; Yeo-Kyeoung Kim; Hoon-Gu Kim; Chul Won Choi; Sung-Hyun Kim; Seong Kyu Park; Eunkyung Park; Yoo Hong Min
Journal:  Haematologica       Date:  2011-06-09       Impact factor: 9.941

Review 4.  A primary care approach to myelodysplastic syndromes.

Authors:  Djamshed Samiev; Vijaya R Bhatt; Joel D Armitage; Lori J Maness; Mojtaba Akhtari
Journal:  Korean J Fam Med       Date:  2014-05-22

Review 5.  What's all the fuss about? facts and figures about bone marrow failure and conditions.

Authors:  Sudipto Mukherjee; Mikkael A Sekeres
Journal:  Curr Hematol Malig Rep       Date:  2012-12       Impact factor: 3.952

6.  Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations.

Authors:  Yoo-Jin Kim; Jun Ho Jang; Jae-Yong Kwak; Je-Hwan Lee; Hyeoung-Joon Kim
Journal:  Blood Res       Date:  2013-06-25

Review 7.  Allogeneic hematopoietic cell transplantation for MDS: for whom, when and how?

Authors:  Boglarka Gyurkocza; H Joachim Deeg
Journal:  Blood Rev       Date:  2012-09-13       Impact factor: 8.250

8.  Clinico-Hematological and cytogenetic spectrum of adult myelodysplastic syndrome: The first retrospective cross-sectional study in Iranian patients.

Authors:  Mostafa Paridar; Kazem Zibara; Seyed Esmaeil Ahmadi; Abbas Khosravi; Maral Soleymani; Ebrahim Azizi; Omid Kiani Ghalesardi
Journal:  Mol Cytogenet       Date:  2021-05-08       Impact factor: 2.009

9.  High bone marrow angiopoietin-1 expression is an independent poor prognostic factor for survival in patients with myelodysplastic syndromes.

Authors:  C-L Cheng; H-A Hou; J-Y Jhuang; C-W Lin; C-Y Chen; J-L Tang; W-C Chou; M-H Tseng; M Yao; S-Y Huang; B-S Ko; S-C Hsu; S-J Wu; W Tsay; Y-C Chen; H-F Tien
Journal:  Br J Cancer       Date:  2011-08-30       Impact factor: 7.640

10.  Distinct clinical and experimental characteristics in the patients younger than 60 years old with myelodysplastic syndromes.

Authors:  Xiao Li; Zhi-jian Xiao; Chun-kang Chang; Feng Xu; Ling-yun Wu; Qi He; Ze-feng Xu; Lu-xi Song; Zheng Zhang; Li-yu Zhou; Ji-ying Su; Xi Zhang; Juan Guo
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.